Tags

Type your tag names separated by a space and hit enter

Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Antimicrob Agents Chemother. 2020 08 20; 64(9)AA

Abstract

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has prompted the repurposing of drugs on the basis of promising in vitro and therapeutic results with other human coronavirus diseases, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). These repurposed drugs have mainly included remdesivir, favipiravir, lopinavir-ritonavir, ribavirin, interferons, and hydroxychloroquine. Unfortunately, the first open-label, randomized, controlled trials are showing poor efficacy of these repurposed drugs. These results highlight the necessity of identifying and characterizing specific and potent SARS-CoV-2 antivirals.

Links

Publisher Full Text
ncbi.nlm.nih.gov
aac.asm.org
PMC Free PDF

Authors+Show Affiliations

Martinez MA
IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain mmartinez@irsicaixa.es.

MeSH

Adenosine MonophosphateAlanineAmidesAntiviral AgentsBetacoronavirusCoronavirus InfectionsDrug Administration ScheduleDrug CombinationsDrug RepositioningHumansHydroxychloroquineInterferonsLopinavirPandemicsPneumonia, ViralPyrazinesRandomized Controlled Trials as TopicRibavirinRitonavirSurvival AnalysisTreatment Outcome

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

32631826

Citation

Martinez, Miguel Angel. "Clinical Trials of Repurposed Antivirals for SARS-CoV-2." Antimicrobial Agents and Chemotherapy, vol. 64, no. 9, 2020.
Martinez MA. Clinical Trials of Repurposed Antivirals for SARS-CoV-2. Antimicrob Agents Chemother. 2020;64(9).
Martinez, M. A. (2020). Clinical Trials of Repurposed Antivirals for SARS-CoV-2. Antimicrobial Agents and Chemotherapy, 64(9). https://doi.org/10.1128/AAC.01101-20
Martinez MA. Clinical Trials of Repurposed Antivirals for SARS-CoV-2. Antimicrob Agents Chemother. 2020 08 20;64(9) PubMed PMID: 32631826.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical Trials of Repurposed Antivirals for SARS-CoV-2. A1 - Martinez,Miguel Angel, Y1 - 2020/08/20/ PY - 2020/7/8/pubmed PY - 2020/9/4/medline PY - 2020/7/8/entrez KW - COVID-19 KW - SARS-CoV-2 KW - antivirals JF - Antimicrobial agents and chemotherapy JO - Antimicrob. Agents Chemother. VL - 64 IS - 9 N2 - The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has prompted the repurposing of drugs on the basis of promising in vitro and therapeutic results with other human coronavirus diseases, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). These repurposed drugs have mainly included remdesivir, favipiravir, lopinavir-ritonavir, ribavirin, interferons, and hydroxychloroquine. Unfortunately, the first open-label, randomized, controlled trials are showing poor efficacy of these repurposed drugs. These results highlight the necessity of identifying and characterizing specific and potent SARS-CoV-2 antivirals. SN - 1098-6596 UR - https://www.unboundmedicine.com/medline/citation/32631826/Clinical_Trials_of_Repurposed_Antivirals_for_SARS_CoV_2_ L2 - http://aac.asm.org/cgi/pmidlookup?view=long&pmid=32631826 DB - PRIME DP - Unbound Medicine ER -